TQB2858 injection
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions
Advanced CancerAdvanced Cervical CancerAdvanced High-grade SarcomaAdvanced Soft-tissue SarcomaEndometrial CarcinomaPancreatic CarcinomaRecurrent / Metastatic Nasopharyngeal CancerTerminal Malignant Tumors
Phase 1
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumors
NCT04805060
Start: 2021-04-23End: 2025-12-12Target: 30Updated: 2021-06-04
A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy
NCT05068921
Start: 2021-12-09End: 2023-07-31Target: 40Updated: 2021-12-13
Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors
TerminatedNCT05154630
Start: 2022-01-14End: 2023-06-30Updated: 2024-01-18
A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma
TerminatedNCT05193604
Start: 2022-03-24End: 2023-11-27Updated: 2023-12-08
To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
NCT05198531
Start: 2022-01-31End: 2023-08-31Target: 90Updated: 2022-01-21
Phase 2
A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma
NCT05121363
Start: 2021-12-31End: 2023-07-31Target: 113Updated: 2021-11-30
Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma
TerminatedNCT05262101
Start: 2022-05-09End: 2023-11-30Updated: 2024-01-22